Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MGNX 
MacroGenics Inc (MGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MGNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.4
1 Year Target Price $3.4
| 2 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 94.99% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.87M USD | Price to earnings Ratio - | 1Y Target Price 3.4 |
Price to earnings Ratio - | 1Y Target Price 3.4 | ||
Volume (30-day avg) 9 | Beta 1.66 | 52 Weeks Range 0.99 - 5.10 | Updated Date 08/29/2025 |
52 Weeks Range 0.99 - 5.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.46 | Actual -0.57 |
Profitability
Profit Margin -21.99% | Operating Margin (TTM) -165.27% |
Management Effectiveness
Return on Assets (TTM) -21.84% | Return on Equity (TTM) -69.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31789305 | Price to Sales(TTM) 0.68 |
Enterprise Value -31789305 | Price to Sales(TTM) 0.68 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 63205700 | Shares Floating 52560599 |
Shares Outstanding 63205700 | Shares Floating 52560599 | ||
Percent Insiders 3.25 | Percent Institutions 80.42 |
Upturn AI SWOT
MacroGenics Inc
Company Overview
History and Background
MacroGenics Inc. was founded in 2000. It is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company has evolved from focusing solely on antibody engineering to developing a pipeline of clinical-stage programs.
Core Business Areas
- Oncology: MacroGenics' primary focus is the development of immunotherapies for various types of cancer.
- MCLA-158: Bispecific ADC targeting EGFR and ADGRG5 in solid tumors
Leadership and Structure
Scott Koenig, M.D., Ph.D. is the President and CEO. The company has a board of directors and operates with a functional organizational structure based on research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Margenza (margetuximab-cmkb): Margenza is an Fc-engineered monoclonal antibody that targets the HER2 protein. It is approved in the US for metastatic HER2-positive breast cancer in combination with chemotherapy, for patients who have received two or more prior anti-HER2 regimens. Competition includes drugs like Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (ado-trastuzumab emtansine) from Roche/Genentech, and Enhertu (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo/AstraZeneca. Market share is currently small but has potential to grow.
- Tebotelimab: An investigational PD-1 x LAG-3 bispecific antibody being evaluated for various cancers. This product is not yet approved. Competitors include the current checkpoint inhibitors such as Keytruda (pembrolizumab) from Merck and Opdivo (nivolumab) from Bristol-Myers Squibb.
- Enoblituzumab: An investigational B7-H3 targeted antibody. This product is not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by long development timelines, high regulatory hurdles, and significant investment in research and development. The oncology sector is particularly dynamic, with rapid advancements in immunotherapy.
Positioning
MacroGenics is positioned as an innovative player in the immuno-oncology space, focusing on developing novel antibody-based therapeutics. Its competitive advantage lies in its proprietary antibody engineering platforms.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be in the hundreds of billions of dollars globally. MacroGenics is positioned to capture a portion of this TAM with its pipeline of novel immuno-oncology drugs. The breast cancer TAM itself is substantial given the prevalence of the disease.
Upturn SWOT Analysis
Strengths
- Proprietary antibody engineering platforms (e.g., DART, TRIDENT)
- Clinical-stage pipeline of immuno-oncology assets
- Approved product (Margenza) provides revenue stream
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on partnerships for some programs
- History of net losses
Opportunities
- Expansion of Margenza into new indications
- Advancement of pipeline candidates through clinical development
- Strategic collaborations and partnerships
- Potential for acquisitions or licensing deals
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- RHHBY
- MRK
- BMY
- AZN
- PFE
Competitive Landscape
MacroGenics competes with larger, more established pharmaceutical companies in the immuno-oncology space. Its competitive advantage lies in its novel antibody engineering platforms, but it faces challenges in terms of resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of rapid stock price appreciation followed by corrections, driven by clinical trial results and regulatory events.
Future Projections: Future growth is dependent on the successful development and commercialization of pipeline candidates. Analyst estimates should be consulted for revenue and earnings projections.
Recent Initiatives: Recent initiatives include clinical trials for pipeline candidates, expansion of the Margenza franchise, and strategic collaborations.
Summary
MacroGenics is a biotech company with a proprietary antibody engineering platform and a clinical-stage pipeline focused on oncology. While it has an approved product, Margenza, it's still reliant on pipeline progress and partnerships. The company faces significant competition and R&D expenses, but has opportunities to expand its product portfolio and market presence. Clinical trial outcomes will strongly influence its trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | CEO, President & Director Mr. Eric Blasius Risser | ||
Sector Healthcare | Industry Biotechnology | Full time employees 341 | Website https://www.macrogenics.com |
Full time employees 341 | Website https://www.macrogenics.com | ||
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.